World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
115
Citations
63505
World Ranking
4460
National Ranking
2431

Overview

Peter A. Calabresi is affiliated with Johns Hopkins University School of Medicine in the United States. Their research primarily spans the field of Medicine, with significant contributions to subfields such as Pathology and Forensic Medicine, Neurology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Ophthalmology.

The scientist has explored a broad range of topics, including:

  • Multiple Sclerosis Research Studies
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Neurogenesis and Neuroplasticity Mechanisms
  • Systemic Lupus Erythematosus Research
  • Peripheral Neuropathies and Disorders
  • Retinal and Optic Conditions
  • Ocular Diseases and Behçet's Syndrome

Peter A. Calabresi's recent papers include:

  • "A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis" (2021, published in Nature)
  • "Diagnosis and classification of optic neuritis" (2022, published in The Lancet Neurology)
  • "APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies" (2021, published in Neurology)
  • "Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation" (2020, published in Journal of Clinical Investigation)
  • "Locus for severity implicates CNS resilience in progression of multiple sclerosis" (2023, published in Nature)

The scientist frequently collaborates with several coauthors, notably Shiv Saidha, Elias S. Sotirchos, Kathryn C. Fitzgerald, Matthew D. Smith, and Ellen M. Mowry, each with dozens of joint publications.

Peter A. Calabresi's scholarly works have appeared predominantly in high-output publication venues such as Neurology, bioRxiv (Cold Spring Harbor Laboratory), Multiple Sclerosis Journal, Annals of Neurology, and Brain.

Best Publications

  • Defining the clinical course of multiple sclerosis: The 2013 revisions

    Fred D. Lublin;Stephen C. Reingold;Jeffrey A. Cohen;Gary R. Cutter

  • A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

    Ludwig Kappos;Ernst Wilhelm Radue;Paul O'Connor;Chris Polman

  • Tract Probability Maps in Stereotaxic Spaces: Analyses of White Matter Anatomy and Tract-Specific Quantification

    Kegang Hua;Jiangyang Zhang;Setsu Wakana;Hangyi Jiang

  • Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

    Richard A. Rudick;William H. Stuart;Peter A. Calabresi;Christian Confavreux

  • Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial†

    Kathleen Hawker;Paul O'Connor;Mark S. Freedman;Peter A. Calabresi

  • Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

    Ludwig Kappos;David Li;Peter A Calabresi;Paul O'Connor

  • Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Peter A. Calabresi;Ernst Wilhelm Radue;Douglas Goodin;Douglas Jeffery

  • Relation of Visual Function to Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis

    Jennifer B. Fisher;Dina A. Jacobs;Clyde E. Markowitz;Steven L. Galetta

  • Saccade preparation inhibits reorienting to recently attended locations.

    Robert D. Rafal;Peter A. Calabresi;Cameron W. Brennan;Toni K. Sciolto

  • A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis.

    Martina Absinta;Martina Absinta;Martina Absinta;Dragan Maric;Marjan Gharagozloo;Thomas Garton

  • Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis

    Axel Petzold;Johannes F de Boer;Sven Schippling;Patrik Vermersch

  • Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases

    Christine Beeton;Heike Wulff;Nathan E. Standifer;Philippe Azam

  • Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

    Amit Bar-Or;Peter A. J. Calabresi;Douglas Arnold;Clyde Markowitz

  • Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

    Amit Bar-Or;Lama Fawaz;Boli Fan;Peter J. Darlington

  • Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA.

    Samantha S. Soldan;Rossana Berti;Nazi Salem;Paola Secchiero

  • Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity

    Michael D. Kornberg;Pavan Bhargava;Paul M. Kim;Vasanta Putluri

  • The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS

    Heike Wulff;Peter A. Calabresi;Rameeza Allie;Sung Yun

  • Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo- controlled, randomized phase II trial

    Ludwig Kappos;Giancarlo Comi;Hillel Panitch;Joel Oger

  • RETINAL NERVE FIBER LAYER IS ASSOCIATED WITH BRAIN ATROPHY IN MULTIPLE SCLEROSIS

    E. Gordon-Lipkin;B. Chodkowski;D. S. Reich;S. A. Smith

  • Imaging outcomes for neuroprotection and repair in multiple sclerosis trials.

    Frederik Barkhof;Peter A. Calabresi;David H. Miller;Stephen C. Reingold

Frequent Co-Authors

Laura J. Balcer
Laura J. Balcer New York University
Elliot M. Frohman
Elliot M. Frohman The University of Texas at Austin
Daniel S. Reich
Daniel S. Reich National Institutes of Health
Jerry L. Prince
Jerry L. Prince Johns Hopkins University
Aaron Carass
Aaron Carass Johns Hopkins University
Dzung L. Pham
Dzung L. Pham Henry M. Jackson Foundation
Peter C.M. van Zijl
Peter C.M. van Zijl Kennedy Krieger Institute
Fred D. Lublin
Fred D. Lublin Icahn School of Medicine at Mount Sinai
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Friedemann Paul
Friedemann Paul Charité - University Medicine Berlin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare career paths is valuable if you're considering studying Medicine in the USA. Online programs now offer more flexibility and accessibility for aspiring professionals at different stages. For those with a non-nursing background, direct entry nurse practitioner programs for non-nurses online present a fast-track option to enter advanced practice roles in nursing.

If you're seeking less competitive admissions, consider institutions known as the easiest rn program choices. These programs often have higher acceptance rates and still provide solid nursing education foundations. Some schools also permit applicants to bypass common entrance exams — check out nursing programs without teas for more details.

Another promising path is in healthcare administration. Accredited medical billing and coding financial aid programs make it easier for students to start a rewarding career with manageable tuition options. Each of these pathways can open doors to respected roles in healthcare — even if your initial path isn't traditional medical school.

Best Scientists Citing Peter A. Calabresi

Trending Scientists